The Journal of Pediatrics
Volume 154, Issue 6 , Pages 854-858 , June 2009

Impact of Clostridium difficile Infection on Pediatric Inflammatory Bowel Disease

  • Filomena Pascarella, MD

      Affiliations

    • Department of Pediatrics, University of Naples “Federico II,” Naples, Italy
    • ,
  • Massimo Martinelli

      Affiliations

    • Department of Pediatrics, University of Naples “Federico II,” Naples, Italy
    • ,
  • Erasmo Miele, MD

      Affiliations

    • Department of Pediatrics, University of Naples “Federico II,” Naples, Italy
    • ,
  • Mariassunta Del Pezzo, MD

      Affiliations

    • Department of Cellular and Molecular Biology and Pathology “Luigi Califano”, University of Naples “Federico II,” Naples, Italy
    • ,
  • Emanuela Roscetto, PhD

      Affiliations

    • Department of Cellular and Molecular Biology and Pathology “Luigi Califano”, University of Naples “Federico II,” Naples, Italy
    • ,
  • Annamaria Staiano, MD

      Affiliations

    • Department of Pediatrics, University of Naples “Federico II,” Naples, Italy
    • Corresponding Author InformationReprint requests: Annamaria Staiano, MD, Department of Pediatrics, University of Naples “Federico II”, Via S Pansini 5, 80131 Naples, Italy

Received 25 August 2008 ,Revised 17 November 2008 ,Accepted 18 December 2008.

References 

  1. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345–351
  2. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–344
  3. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–210
  4. Kelly CP, Pothoulakis C, LaMont TJ. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262
  5. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile–related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2007;13:1417–1419
  6. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1–15
  7. Greenfield C, Aguilar Ramirez JR, Pounder RE, Williams T, Danvers M, Marper SR, et al. Clostridium difficile and inflammatory bowel disease. Gut. 1983;24:713–717
  8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657
  9. Bousvaros A, Morley-Fletcher A, Pensabene L, Cucchiara S. Research and clinical challenges in paediatric inflammatory bowel disease. Dig Liver Dis. 2008;40:32–38
  10. Irving PM, Gibson PR. Infections and IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:18–27
  11. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775–778
  12. Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis. 2002;8:213–218
  13. Meyer AM, Ramzan NN, Loftus EV, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38:772–775
  14. Stone CD. Prognosis in Clostridium difficile infection complicating inflammatory bowel disease. Gut. 2008;57:150–152
  15. Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr. 1991;13:39–41
  16. Chong SK, Blackshaw AJ, Boyle S, Williams CB, Walker-Smith JA. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut. 1985;26:55–59
  17. Lichtiger S, Present D, Kornbluth A, Gelerent I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med. 1994;330:1841–1845
  18. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439–447
  19. Staneck JL, Weckbach LS, Allen SD, Siders JA, Gilligan PH, Coppitt G, et al. Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C difficile, cytotoxin assay, culture, and latex agglutination. J Clin Microbiol. 1996;34:2718–2721
  20. Schumacher G, Kollberg B, Sandstedt B, Jorup C, Grillner L, Ljungh A, et al. A prospective study of first attacks of inflammatory bowel disease and non-relapsing colitis: microbiologic findings. Scand J Gastroenterol. 1993;28:1077–1085
  21. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57:549–558
  22. Tremaine WJ, Bille J, Huizenga KA, Washington JA, Ilstrup DM. Factors which influence the occurrence of Clostridium difficile infections in inflammatory bowel disease [abstract]. Gastroenterology. 1983;4:1337
  23. Keighley MR, Youngs D, Johnson M, Allan RN, Burdon DW. Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut. 1982;23:410–414
  24. Wiström J, Norrby SR, Myhre EB, Eriksson S, Granström G, Lagergren L, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001;47:43–50
  25. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336:97–100
  26. Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ. Characteristics and incidence of Clostridium difficile–associated disease in The Netherlands, 2005. Clin Microbiol Infect. 2007;13:1058–1064
  27. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of C difficile infection. N Engl J Med. 1989;320:204–210
  28. Dial S, Alrasadi K, Manouykian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pomp inhibitors: cohort and case-control studies. CMAJ. 2004;171:33–38
  29. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid–suppressive agents and the risk of community-acquired Clostridium difficile–associated disease. JAMA. 2005;294:2989–2995
  30. Hauben M, Horn S, Reich L, Younus M. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools. Int J Infect Dis. 2007;11:417–422
  31. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile–associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103:2308–2313

 The authors declare no conflicts of interest.

PII: S0022-3476(08)01143-8

doi: 10.1016/j.jpeds.2008.12.039

The Journal of Pediatrics
Volume 154, Issue 6 , Pages 854-858 , June 2009

Article Tools

* Image Usage & Resolution